CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months

Can-Fite BioPharma Ltd. Sponsored ADR

Can-Fite BioPharma Ltd. Sponsored ADR

CANF

0.00
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.